

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 January 2004 (08.01.2004)

PCT

(10) International Publication Number
WO 2004/003165 A2

- (51) International Patent Classification⁷: C12N (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, A7, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (21) International Application Number: PCT/US2003/020601
- (22) International Filing Date: 30 June 2003 (30.06.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/392,675 28 June 2002 (28.06.2002) US
- (71) Applicant (*for all designated States except US*): IM-CLONE SYSTEMS INCORPORATED [US/US]; 180 Varick Street, New York, NY 10014 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): PEREIRA, Daniel [US/US]; 11 Bolten Place, Bloomfield, NJ 07003 (US).
- (74) Agents: SOMERVILLE, Deborah, A. et al.; Kenyon & Kenyon, One Broadway, New York, NY 10004 (US).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL POLYNUCLEOTIDE AND POLYPEPTIDE SEQUENCES AND USES THEREOF

(57) Abstract: The present invention provides a purified nucleic acid encoding a putative transmembrane receptor polypeptide comprising at its N-terminus leucine rich repeats and at least an immunoglobulin domain. S30-21616/DEGA polypeptide of the present invention, analogs of said polypeptide, vectors and host cells that embody the polynucleotides, bio-immunopharmaceutical compositions and diagnostic reagents comprising the polypeptides, analogs and derivatives and methods for making and utilizing the polypeptides are disclosed.

BEST AVAILABLE COPY

WO 2004/003165 A2

NOVEL POLYNUCLEOTIDE AND POLYPEPTIDE SEQUENCES AND USES THEREOF

FIELD OF THE INVENTION

[01] The present invention relates to polynucleotides and polypeptides that are differentially expressed in a diseased cell and methods of diagnosis, evaluation, treatment, and prevention of diseases relating thereto.

BACKGROUND OF THE INVENTION

[02] Cancer is the second leading cause of death in the United States, exceeded only by heart disease. In 2002, the American Cancer Society estimated that 1,284,900 new cases will be diagnosed and 550,000 of the 1.6 million living with cancer are expected to die. Cancer is caused by genetic alteration or malfunction of the genes in the cell that results in uncontrolled proliferation of the abnormal cells to form a tumor mass or neoplasm. One of the major factors contributing to uncontrolled proliferation of cells is the over-expression of proto-oncogenes and/or under-expression of tumor suppressor genes. Both these genes play a pivotal role in cancer pathogenesis and the imbalance in polynucleotide expression of these two polynucleotide families perpetuates cancer immortalization. Classes of oncogenes and tumor suppressor genes and polypeptides include growth factors, such as epidermal growth factor (EGF) and transforming growth factor α (TNF- α) and their corresponding receptors, intracellular signaling polypeptides (tyrosine kinases), polynucleotide transcription factors, cell-cycle control polypeptides, and cell-cell or cell-matrix interacting polypeptides.

[03] Uncontrolled cell growth leads to the formation of a localized tumor cell mass, the viability of which is maintained by the formation of neo-vasculature such as blood capillaries that are essential for ferrying nutrients to the cells. Angiogenesis is therefore a key element in the survival, growth, and metastasis of tumors. Polypeptides that are known to play a vital role in angiogenesis are growth factors and their corresponding receptors, including EGF and TGF- α , as well as vascular endothelial growth factor (VEGF).

[04] The localized tumor mass, with its continued rapid cell proliferation, ultimately results in invasion of adjacent tissues as the tumor cells break away from the original tumor mass and migrate to regional lymph nodes and distal vital structures in the body via blood or lymphatic systems. The invasion of tumor cells requires adhesion of cells to the extra-cellular matrix, followed by its breakdown, and finally migration of the tumor cell. The dissemination of certain cancers to preferred sites have been shown to be determined by the presence of certain polypeptides on the cell surface that are capable of homing in on selected cell surface markers on target cells.

[05] Thus, inhibition of uncontrolled cell proliferation, angiogenesis, and cell spread are some of the key targets in the development of therapeutics for managing tumor progression and recurrence. Although much progress has been made in the field of cancer and cancer therapy, many of the therapies in development today has been less than satisfactory, and a need still exists for alternative adjuvant therapy for many of these specific tumor types. The present application involves the discovery of a novel polynucleotide encoding a polypeptide or polypeptide that is differentially expressed in certain tumor cells and can be useful in the diagnosis, evaluation, treatment, and prevention of cancer.

SUMMARY OF THE INVENTION

[06] The present invention provides isolated and/or purified human and mouse S30-21616/DEGA polynucleotides (*hS30-21616/DEGA* or *mS30-21616/DEGA* respectively), particularly SEQ ID NO:1 and SEQ ID NO:3, or a fragment thereof. The present invention also provides isolated and/or purified human and mouse S30-21616/DEGA polypeptides (*hS30-21616/DEGA* and *mS30-21616/DEGA*), particularly SEQ ID NO:2 and SEQ ID NO:4, or a fragment thereof. In addition, the present invention provides methods and compositions for diagnosis, evaluation, treatment, and prevention of diseases using such polynucleotides or polypeptides.

BRIEF DESCRIPTION OF THE DRAWINGS

[07] Figure 1 depicts the nucleotide and deduced amino acid sequence of S30-21616/DEGA (cDNA = 3769 bp; ORF = 1569 bp, which encodes a polypeptide of 522 amino acids) with the following features: signal peptide sequence (**bold**); transmembrane domain (**bold underline**); putative glycosylation sites (**circled amino acids**) and putative phosphorylated serines and threonines (**boxed amino acids**)

[08] Figure 2 A and B show the dot blot analyses of S30-21616/DEGA cDNA expression levels in tumor and normal tissue samples of individual patients using BD Biosciences Cancer Profiling Arrays I (A) and II (B).

[09] Figure 3 shows the Northern blot analysis of S30-21616/DEGA expression in gastric adenocarcinoma cell lines, AGS (Lane A), NCI-N87 (Lane B), RF-1 (Lane C), KatoIII (Lane D), KKVR (Lane E), NCI-SNU-16 (Lane F), and NCI-SNU-1 (Lane G). The bottom panel shows the mRNA level of β -actin in the respective cell lines.

[10] Figure 4 shows the dot blot analysis of S30-21616/DEGA expression in general, non-gastric adenocarcinoma cell lines.

[11] Figure 5A shows the schematic representation the S30-21616/DEGA protein. Domains present in the S30-21616/DEGA protein are shown with their amino acid boundaries as follow: SP=Signal Peptide; LRR=Leucine-Rich Repeat; LRR-NT=Cysteine-rich domain N-terminally flanking LRR; LRR-CT=Cysteine-rich domain C-terminally flanking LRR; IgG=Immunoglobulin domain; TM=transmembrane domain; and S/T-Rich=Serine/Threonine-Rich domain. Black diamonds represent putative N-linked glycosylation sites. Figure 5B shows the amino acid sequence of the S30-21616/DEGA polynucleotide with the LRR **bolded**, the immunoglobulin-like domain underlined, the transmembrane domain **boxed**, and the casein kinase phosphorylation and polypeptide kinase C phosphorylation sites indicated by [] and (), respectively.

[12] Figure 6 illustrates the sub-cellular localization of the S30-21616/DEGA-EGFP (Enhanced Green Fluorescent Protein) fusion protein that was stably expressed in 293 cells and assessed using fluorescence microscopy (200X magnification).

[13] Figure 7 shows the Northern blot analysis S30-21616/DEGA expression in AGS parental or wild type cells (Lane 1), AGS transfected with empty vector, AGS/empty vector clone #15 (Lane 2), AGS transfected with S30-21616/DEGA antisense, AGS/DEGA antisense clone #6 (Lane 3) and AGS/DEGA antisense clone #11 (Lane 4). The bottom panel shows the endogenous expression of β -actin mRNA in the respective cell types (internal control).

[14] Figure 8 (left panel) shows the flow cytometric histograms of the DNA contents/cell cycle profiles of AGS empty vector clone #15 (top left panel), AGS/DEGA antisense clone #6 (middle left panel) and AGS/DEGA antisense clone #11 (bottom left panel). Figure 8 (right panel) shows the light microscopy comparing the cell size of AGS antisense clone #6 (middle right panel) and clone #11 (bottom right panel) to AGS/empty vector clone #15 (top right panel).

[15] Figure 9 illustrates the tumorigenic growth curves of AGS clones stably transfected with antisense DEGA construct or empty vector determined by the number of tumor-bearing mice versus the total number of mice injected, as follow: AGS WT (12/12); AGS/empty vector clone #15 (19/19); AGS/DEGA antisense clone #6 (6/12); and AGS/DEGA antisense clone #11 (6/19).

DETAILED DESCRIPTION OF THE INVENTION

[16] The present invention relates to the isolation of novel polynucleotide sequences from a lung carcinoma cell line, A549 cDNA (BD Biosciences/Clontech, Palo Alto, CA), having a 1569 nucleotide open reading frame. This human nucleotide sequence is referred to as *hS30-21616* or *hS30-21616/DEGA* due to its Differential Expression Profile in Gastric Adenocarcinoma. The mouse counter-part of this polynucleotide sequence, *mS30-2161/DEGA*, which is differentially expressed in a hematopoietic stem cell subtractive cDNA library and in a mouse kidney cancer cell line, has also been isolated. Accordingly, the present invention provides a

polynucleotide encoding both a human (hS30-21616/DEGA) and mouse (mS30-21616/DEGA) S30-21616/DEGA polypeptide.

[17] The polynucleotides of the present invention can be DNA, RNA, DNA/RNA duplexes, polypeptide-nucleic acid (PNA), or derivatives thereof. The polynucleotide sequence includes fragments or segments that are long enough to use in polymerase chain reaction (PCR) or various hybridization techniques well known in the art for identification, cloning and amplification of all or part of mRNA or DNA molecules. For example, hybridization under high stringency conditions means the following nucleic acid hybridization and wash conditions: hybridization at 42° C in the presence of 50% formamide; a first wash at 65° C with 2 X SSC containing 1% SDS; followed by a second wash at 65° C with 0.1 X SSC. In addition, the polynucleotides of the present invention include complements of any of the nucleotide or peptides recited above, e.g., cDNA and mRNA.

[18] As used herein, "isolated" or "purified" means that a molecule, e.g., a polynucleotide or polypeptide, is separated from cellular material or other components that naturally accompany it. Typically, the polynucleotide or polypeptide is substantially pure when it is at least 60% (by weight) free from the proteins and other naturally occurring organic molecules with which it is naturally associated. Preferably, the purity of the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99% (by weight) free. A substantially pure polynucleotide or polypeptide can be obtained, e.g., by extraction from a natural source, expression of a recombinant nucleic acid encoding the polypeptide, or chemical synthesis. Purity can be measured by any appropriate method, e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis. It should be appreciated that the term isolated or purified does not refer to a library-type preparation containing a myriad of other sequence fragments. A chemically synthesized polynucleotide or polypeptide or a recombinant polynucleotide or polypeptide produced in a cell type other than the cell type in which it naturally occurs is, by definition, substantially free from components that naturally accompany it. Accordingly, substantially pure polynucleotides or polypeptides include those having sequences derived from eukaryotic organisms but produced in *E. coli* or other prokaryotes.

[19] The isolated nucleic acid or polynucleotides of the present invention preferably have a nucleotide sequence of SEQ ID NO:1 (*hS30-21616/DEGA*) and SEQ ID NO:3 (*mS30-21616/DEGA*), or a fragment thereof. Alternatively, and also preferably, the polynucleotides encode a polypeptide with the amino acid sequence of SEQ ID NO:2 (*hS30-21616/DEGA*) and SEQ ID NO:4 (*mS30-21616/DEGA*), or a fragment thereof at least eight amino acids in length.

[20] The polynucleotides further include degenerate variants, homologues, or mutant forms of the polynucleotide sequence. By degenerate variant, the term refers to changes in polynucleotide sequences, particularly in the third base of the codon, that do not affect the amino acid sequence encoded by the nucleotide sequences. The term homologue refers to a polynucleotide sequence from a different species having equivalent structure and/or function. Mutant forms refer to alterations of the polynucleotide sequence, such as addition, deletion, or substitution of one or more nucleotides using recombinant DNA techniques well known in the art, or which have been selected naturally. Kunkel et al. (1987) *Meth. Enzymol.* 154: 367-382-382.

[21] The polynucleotide sequences falling within the scope of this invention include nucleotide sequences that are substantially equivalent to the polynucleotide sequences of SEQ ID NO:1 or SEQ ID NO:3 recited above. Polynucleotide sequences of the above invention can have at least about 80%, preferably 90%, and more preferably 95% sequence identity to the polynucleotide recited in SEQ ID NO:1 or SEQ ID NO:3.

[22] The polynucleotides of the present invention encode a polypeptide (*S30-21616/DEGA* polypeptide). Accordingly, the present invention provides isolated and/or purified *S30-21616/DEGA* polypeptides. In one embodiment of the present invention, the *S30-21616/DEGA* polynucleotide encodes an *S30-21616/DEGA* polypeptide comprising approximately 523 amino acids. In another embodiment, the polypeptide is expressed on the surface of a cell. Preferably, the *S30-21616/DEGA* polypeptide of the present invention has an amino acid sequence of SEQ ID NO:2 (*hS30-21616/DEGA*) and SEQ ID NO:4 (*mS30-21616/DEGA*), or a fragment thereof at least eight amino acids in length.

[23] These polypeptides include functional equivalents, homologues, or mutant forms of the polynucleotide sequence. By functional equivalent, the term refers to alterations in the amino acid sequence, including additions, deletions, and substitutions, that do not substantially alter polypeptide characteristics, e.g., charge, IEF, affinity, avidity, conformation, solubility, and retain the specific function or immunological cross-reactivity of the polypeptide. The term functional equivalents includes conservative amino acid substitutions, which involves a change in the amino acid sequence by way of substituting amino acids of the polypeptide with amino acids having generally similar properties, e.g., acidic, basic, aromatic, size, positively or negatively charged, polarity, non-polarity. The term homologue refers to a polypeptide sequence from a different species having equivalent characteristics and/or function. Mutant forms refer to alterations of the polypeptide sequence, arising due to splicing, polymorphisms, or other events and which may have been selected naturally.

[24] The polypeptide sequences falling within the scope of this invention include amino acid sequences that are substantially equivalent to the polypeptide sequences of SEQ ID NO:2 or SEQ ID NO:4 recited above. Polypeptide sequences of the above invention can have at least about 80%, preferably 90%, and more preferably 95% sequence identity to the polypeptide recited in SEQ ID NO:2 or SEQ ID NO:4.

[25] Preferably, the polypeptides of the present invention have, in a continuous manner, an extracellular N-terminus domain, a transmembrane domain and an intracellular C-terminus domain. *See, e.g.,* Figure 5. Such polypeptides include the full length and any extracellular or intracellular variants of the S30-21616/DEGA polypeptide, including, e.g., the soluble variant resulting from deletion of the transmembrane domain (SEQ ID NO:5).

[26] One function of this S30-21616/DEGA polypeptide, although by no means the only function, is a cell surface transmembrane receptor. Transmembrane receptors include, e.g., polypeptide kinases, which are enzymes that catalyze the transfer of a phosphate group from ATP to specific amino acid residues in a target substrate polypeptide. These enzymes are important in a variety of cellular events ranging from signal transduction to membrane transport. Tyrosine polypeptide kinases are involved

in mitogenic signaling that initiates rapid signal transduction, while serine/threonine kinases generally integrate and amplify signals.

[27] In addition, S30-21616/DEGA polypeptides may also function as a cell adhesion molecule (CAM). CAMs are a diverse group of glycopolypeptides and carbohydrate molecules that are expressed on the surface of every cell type in unique patterns, depending on the cell type, state of activation of the cell and cell function. These molecules selectively recognize and bind to each other in order to mediate adhesion between cells and also between cells and the extracellular matrix molecules to provide a "VELCRO® effect," allowing cells to explore their environment (see Shimaoka et. al, (2002) *Annu. Rev. Biophys. Biomol. Struc.* 31:485-516; Wang and Springer (1998) *Immunol. Rev.* 163:197-215). CAMs are known to play a role in various cellular processes, including, but not limited to, the following processes: (1) organ/tissue development and integrity, (2) initiation and propagation of immune responses, (3) migration or trafficking of immune and inflammatory cells to inflammation sites, (4) wound healing, (5) cancer metastasis, (6) cell signaling, and (7) as selective sites of entry by viral and bacterial pathogen (Cassanova et al. (1998) *J. Virol.* 72:6244-6246).

[28] Some examples of CAMs include, but are not limited to, selectins, which recognize carbohydrates; integrins, which are primarily expressed on leukocytes and platelets; and members of the immunoglobulin superfamily, which are expressed on both endothelial cells and leukocytes. Members of the immunoglobulin superfamily include intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and L-1 family of neural adhesion molecules. Binding of CAMs may be calcium dependent or calcium independent. Examples of calcium dependent adhesion molecules include cadherins (epithelial E- and P-cadherins, desmosomal cadherins in epidermis and placenta, and N-cadherins found mostly in nerves, muscles and lens cells), selectins, and integrins (also magnesium dependent). Non-calcium dependent CAMs belong to the immunoglobulin (Ig) superfamily. Binding of CAMs to its ligands often trigger the signaling cascade, which involves various kinases such as polypeptide kinase C (PKC), mitogen-activated polypeptide kinase (MAPK), focal adhesion kinase (FAK) and phospholipase C' (PLC).

[29] Thus, in one embodiment of the present invention, agents or small molecules capable of disrupting interaction between CAMs and their ligand, or inhibiting the kinases, can be used, for example, to control tumor cell growth. Examples of methods for screening small molecules are described below. In another embodiment of the invention, the nucleotide sequence encoding domain(s) of the polypeptide identified to play a critical role in cell adhesion may be mutated, thereby rendering the molecule incapable of binding to its normal target. Another embodiment of the invention includes engineering such a domain to enhance cell adhesion with various degree of binding to its ligand.

[30] The definition of polypeptide in the present invention also includes within its scope variants or analogs thereof. The term variant is intended to include polypeptides having amino acid additions, including, but not limited to, addition of methionine and/or leader sequences to promote translation and secretion; addition of amino acid sequences or tags to facilitate purification (e.g. polyhistidine sequences); and addition of other polypeptide sequences to produce fusion polypeptides. The term "variant" is also intended to include polypeptides having amino acid deletions of the amino or carboxyl terminus or regions responsible for retention, such as, but not limiting to, the transmembrane region in the polypeptide sequence of S30-21616/DEGA. The present invention includes a polypeptide variant or analog lacking the transmembrane region, resulting in a soluble polypeptide. The term "variant" is also intended to include polypeptides having modifications to one or more amino acid residues that are compatible with the function and structure of the polypeptide. Such modifications include glycosylation, phosphorylation, sulfation and lipidation.

[31] The polypeptide variants or analogs contemplated include polypeptides purified and isolated from a natural source, such as a tumor cell, or recombinantly synthesized; the variant polypeptide having amino acid sequences that differ from the exact amino acid sequence as a result of conservative substitutions, e.g., of the amino acid sequence in SEQ ID NO:2 and SEQ ID NO:4. Conservative amino acid substitutions, as recognized by persons skilled in the art, are changes in amino acid sequence compatible with maintaining the function and structure of the polypeptide.

[32] In a preferred embodiment of the invention, the S30-21616/DEGA polypeptide has a leucine-rich extracellular N-terminus portion, i.e., leucine rich repeats (LRR) of SEQ ID NOS:6, 7, 8, 9, 10, 11 or 12 and an Ig domain of SEQ ID NO:13. *See, e.g.*, Figure 1. Generally, leucine rich polypeptides are known to play a major role in polypeptide-polypeptide interactions in the cell matrix or on the cell surface. The specificity and diversity of the polypeptide-polypeptide interactions may arise from the non-consensus residues flanking the sequence.

[33] Immunoglobulin or Ig-domains, as the term implies, are domains within classes of polypeptide that, similarly to heavy and light chains of immunoglobulins, are well defined regions composed entirely of pairs of β strands or sandwich. These β strands (sheets) or sandwich serve as potential sites for intermolecular recognition. Ig-domains generally function either as structural scaffolds or mediate specific intermolecular interactions with other polypeptides, DNAs, or phospholipids. As structural scaffolds, a series of Ig-domains may serve as building blocks with one domain having intermolecular binding properties and the others interacting with adjacent domains. Examples of polypeptides having Ig-domains as structural scaffolds include the heavy and light chains of immunoglobulins (Amzel & Poljak (1979) *Annu. Rev. Biochem.* 48:961-997), extracellular domains of T and B cell receptors (Garcia (1999) *Annu. Rev. Immunol.* 17:369-397), major histocompatibility complexes (Hennecke & Wiley (2001) *Cell* 104:1-4), growth factors (de Vos et al. (1992) *Science* 255:306-312), cytokine receptors (Deller & Jones (2000) *Curr. Opin. Struc. Biol.* 10:213-219) and adhesion molecules (Chothia & Jones (1997) *Annu. Rev. Biochem.* 66:823-862). Preferably, the Ig-domain of the S30-21616/DEGA polypeptide has the amino acid sequence of SEQ ID NO:13. *See, e.g.*, Figure 5B.

[34] In another embodiment of the present invention, the S30-21616/DEGA polypeptide is a soluble polypeptide having at least one LRR and the possibility of an Ig-domain. Preferably, the LRR motifs generally comprise of 20-29 residues that harbor a conserved eleven residue consensus segment (LXXLXLXXLXL), where X can be any amino acid and L can be a leucine, valine, isoleucine or phenylalanine residue. Such a polypeptide is at least a monomer; the polypeptide can also be a multimer and preferably a dimer. In another embodiment, the dimer or multimer can be a homodimer or homomultimer. In another preferred embodiment, the dimer or

multimer can be a heterodimer or heteromultimer. Alternatively, the S30-21616/DEGA polypeptide is a membrane bound S30-21616/DEGA polypeptide having at least one LRR and an Ig-domain.

[35] The C-terminus domain of the S30-21616/DEGA polypeptide in the present invention has serine and threonine phosphorylation sites that may serve as binding sites for various kinases, e.g., casein kinase II (CKII) and polypeptide kinase C (PKC) phosphorylation sites and may thus function as a signaling receptor. *See, e.g.*, Figure 1. Phosphorylation of either or both the CKII and PKC sites result in intracellular signaling, which often leads to, e.g., uncontrolled cell growth. The present invention includes variants or analogs of the polypeptides having alterations specifically in the C-terminus CKII and PKC sites, such that modulation of phosphorylation and hence signaling can be modulated.

[36] Moreover, the predicted initiating methionine and surrounding sequence (ACCATAATGT) of Figure 1 resembles the Kozak consensus sequence. Potential polyadenylation sequences are underlined. Features of the S30-21616/DEGA protein sequence are as follow: signal peptide sequence (bold); transmembrane domain (bold underline); putative glycosylation sites (circled amino acids) and putative phosphorylated serines and threonines (boxed amino acids).

[37] In one embodiment of the present invention, recombinant constructs are provided. These constructs comprise a S30-21616/DEGA polynucleotide, particularly, SEQ ID NO:1 and SEQ ID NO:3, or a fragment thereof, and a suitable vector, including, but not limited to, a plasmid or viral vector, phagemid, cosmid, phage vector or derivative useful for expression, replication, probe generation and sequencing purposes. Such constructs can be used to modulate S30-21616/DEGA function.

[38] S30-21616/DEGA function can be up- or down-regulated by modulating the transcriptional or translational control of the nucleic acid in the cell, resulting in inhibition of S30-21616/DEGA polynucleotide expression or altering the amount of S30-21616/DEGA polypeptide. By up-regulation, it is meant that the activity associated with S30-21616/DEGA is enhanced, while down-regulation means

diminished or inhibition of the activity. S30-21616/DEGA polynucleotide expression control can be at the level of DNA or RNA. At the DNA level, the functions that can be inhibited includes replication or transcription. The functions of RNA to be interfered with include translocation of RNA to the site of polypeptide translation, translation of polypeptide from the RNA, splicing of RNA to yield one or more mRNA species, and catalytic activity which can be engaged in or facilitated by the RNA.

[39] One agent or construct that can inhibit S30-21616/DEGA polynucleotide expression is an antisense oligonucleotide, which can be in the form of DNA or RNA, or a hybrid thereof. Antisense oligonucleotides can be cDNA, genomic DNA or synthetic RNA or DNA. The DNA can be double-stranded or single stranded, and if single stranded can be the coding or non-coding strand. By antisense, it is referred to specific hybridization of the oligomer with its target nucleic acid, resulting in interference with the normal function of the nucleic acid. All functions of the DNA can be interfered with by antisense, including replication and transcription. Moreover, all functions of the RNA can be interfered with by antisense, including translocation of the RNA to the site of protein translation, translation of protein from mRNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which can be engaged in or facilitated by RNA, for example. The overall effect of such antisense oligonucleotide is inhibition of expression of S30-21616/DEGA in a cell, which may result in reduced DNA transcription, RNA translation, and polypeptide production.

[40] Preferably, the antisense oligonucleotide has a portion of nucleotide sequence of SEQ ID NO:1 and SEQ ID NO:3, or the complement thereof. Also preferably, the antisense oligonucleotide is complementary to a portion of a nucleotide sequence encoding all or a portion of a S30-21616/DEGA polypeptide of SEQ ID NO:2 and SEQ ID NO:4. Preferably, the antisense oligonucleotide comprises short, gene-specific sequences of S30-21616/DEGA nucleic acid of 20-30 nucleotides in length and more preferably between 12-25 nucleotides in length.

[41] The antisense oligonucleotides of the present invention can be delivered into a cell by any suitable methods, including receptor-mediated endocytosis, micro-

injection and via DNA-protein complexes or cationic liposomal encapsulation. Another method of improving delivery is by attaching receptor ligands or cell specific antibodies to the antisense oligonucleotide sequences to assist in directing and guiding them to particular target cells and/or tissue regions.

[42] One of the major problems with using antisense oligonucleotide as a therapeutic molecule is the rapid enzymatic degradation of oligonucleotides in blood and in cells. One solution is to terminally inverting the polarity of the oligonucleotide. This concept is based on the assumption that intracellular degradation is mainly due to exonuclease, and consequently, modifications at the ends of the oligonucleotides would stabilize the sequence.

[43] Another proposed solution is via modification of the phosphodiester bonds between nucleotide bases to form, for example, phosphorothioate bonds by substituting one or more non-linking oxygen in the phosphate backbone with sulfur atoms to form, for example, monothiophosphate, and dithiophosphates. These modified oligonucleotides have been shown to have increased half lives. In addition to the sulfur modification, other types of modification in the sugar-phosphate backbone of the anti-sense oligonucleotide include, but not limited to, a 3' amino group substituted for a 3' hydroxyl group in the 2' deoxyribose ring of the DNA (phosphoramidate modification), 2' O-methyl oligo-ribonucleoside phosphodiester, methylphosphonates (addition of a methyl group to the non-linking oxygen in the phosphodiester backbone), and phosphotriester.

[44] A second generation of anti-sense oligonucleotide include mixed-backbone oligonucleotides which may contain monothiophosphate modification at both the 3' and 5' end of the oligonucleotide. Other examples of modifications include for example, 3'-deoxy-3'-(2-N, N-diphenyliminidazolidino)-thymidine-5'-N,N,-diisopropyl-O-methylphosphoramidite, 3'-deoxy-3'-(2-N, N-diphenyliminidazolidino)-thymidine-5'-O-methylphosphite. Examples of potential modifiers include for example, but not limited to hydrazine, succinate, ethylenediamine and many others. Alternatively, the 3' position of the unmodified phosphodiester bond can be substituted with a carbon in the P-O linkage to form a 3' methylene or 3'-hydroxymethylene linkage.

[45] One of the side-effects of using antisense oligonucleotides concerns the recognition by the immune system that the antisense oligonucleotide is a foreign molecule, particularly, oligonucleotides that contain the two-base sequence, unmethylated CpG (Cytosine-phosphate-Guanine), which are commonly found in bacteria DNA and not in mammalian DNA. A potential solution is to methylate such an oligonucleotide. Other methods of minimizing the side effects of oligonucleotide treatment involves slow administration of the oligonucleotides in low doses by continuous intravenous injection (instead of administering high doses over a short period of time) and developing topical deliver vehicles that allow for sufficient delivery of the oligonucleotide via the epidermis.

[46] It is also possible to inhibit S30-21616/DEGA expression by inactivating the nucleotide sequence encoding the S30-21616/DEGA polypeptide and hence decreasing or inhibiting polypeptide expression. Such inactivation can occur by deleting the nucleotide sequence in the cell or by introducing a deletion or mutation into the nucleotide sequence, thereby inactivating the nucleotide sequence. The nucleotide sequence can also be inactivated by inserting into the polynucleotide another DNA fragment such that expression of endogenous S30-21616/DEGA does not occur. Methods for introducing mutations, such as deletions and insertions, into genes in eukaryotic cells are well known in the art, e.g., U.S. Patent No. 5,464,764. Oligonucleotides and expression vectors useful for mutation of genes in cells can be made according to methods known in the art and guidance provided herein; for example, methods useful for making and expressing antisense oligonucleotide scan be used to make oligonucleotides and expression vectors useful for mutating genes in cells.

[47] In another embodiment of the present invention, S30-21616/DEGA function or expression can be up-regulated or induced in a cell. Examples of up-regulation include but are not limited to administration to the cell of naked nucleic acids (naked DNA vectors such as oligonucleotides or plasmids), or polypeptides, including recombinantly produced polypeptides. Recombinantly produced polypeptides means that the DNA sequences encoding S30-21616/DEGA are placed into a suitable expression vector, which is described in detail below.

[48] The S30-21616/DEGA polynucleotides of the present invention in a recombinant construct may be operably linked to an expression control sequences or promoters, such control sequences are known in the art. Kaufman, *Meth. Enzymol.* (1990) 185:537. The recombinant vector will also include origin of replication to ensure maintenance of vector, one or more selectable markers, leader sequences useful for directing secretion of translated polypeptide into the periplasmic space or extra-cellular medium of host cell.

[49] Targeted mutagenesis and gene replacement of an exogenous human polynucleotide into a non-human mammal (e.g. mouse) provides an *in vivo* research tool for the study and understanding of the biochemical and physiological functions of the polynucleotide. In addition, transgenic non-human mammals also allow for the identification of molecular targets, regulators and therapeutic strategies for the treatment and prevention of diseases or conditions associated with said polynucleotide. Thus, the present invention relates to a transgenic mammals (e.g. mouse) having a non-native nucleotide sequence from another organism inserted into its genome through, e.g., recombinant DNA techniques, which are herein referred to as S30-21616/DEGA transgenics. In addition, the present invention relates to mammals that lack a functional *mS30-21616/DEGA* polynucleotide, herein referred to as S30-21616/DEGA knockouts, which can be generated using methods well known in the art. Cappecchi, *Science* (1989) 244:1288-1292.

[50] In one embodiment of the invention, a conventional knockout non-human mammal is developed, wherein both alleles of the *mS30-21616/DEGA* are entirely absent from the cells. In another embodiment of the transgenic non-human mammal, *mS30-21616/DEGA* is totally replaced and only the *hS30-21616/DEGA* polynucleotide is expressed. In a preferred embodiment of the present invention, a conditional knockout is envisioned, wherein the *mS30-21616/DEGA* polynucleotide is deleted in a particular organ, cell type, or stage of development. Wagner, *Development* (2002) 129:1377-1386.

[51] Human S30-21616/DEGA is found to be up-regulated in certain types of tumor cells, such as stomach and thyroid cancers, but generally down-regulated in breast, lung and ovarian cancers. Expression is generally low in normal or non-

neoplastic tissue samples and may therefore be useful as a molecular marker for the diagnosis of various cancers. It is therefore an object of this invention that the expression or lack of expression of this polynucleotide can be used to determine the predisposition of an animal, preferably a human subject, of a specific cancer such as, but not limiting to, for example, stomach cancer. Specifically contemplated is a kit, useful in the diagnosis or prognosis of cancer, having a DNA or antisenseDNA or RNA probe derived from the sequences of the S30-21616/DEGA polynucleotide and its variants, in a mixture of reagents well known in the art.

[52] In another embodiment of this invention, the S30-21616/DEGA polynucleotide and/or S30-21616/DEGA polypeptide can be either up-regulated and/or down-regulated. For example, up-regulation or down-regulation of the S30-21616/DEGA on the surface of the cell or secreted into the serum of the patient with cancer can be used diagnostically to confirm or rule out suspected cancer. As a serum or cell surface biomarker, the level of expression of the polypeptide at the time of diagnosis may also provide a more precise prognosis than by staging alone. An immunoassay kit having, e.g., an antibody directed to the polypeptide or a peptide derived from the ligand binding to the polypeptide is envisioned for the present invention. The read-outs for the assays are from standard immunoassays well known in the art. Examples of such assays include, but are not limiting to, enzyme-linked immunosorbent assay (ELISA), radio-immunolabelled assay (RIA), immunoblots and fluorescein-activated cell sorting (FACs).

[53] The invention also discloses a method to purify and produce the full length, extracellular or intracellular variants of the polypeptide. For example, one embodiment of the invention provides recombinant constructs comprising a nucleic acid of SEQ ID NO:1 and SEQ ID NO:3 having the polynucleotide sequence or fragment thereof, and a suitable expression vector operably linked to a promoter and a leader sequence for expression in a prokaryotic or eukaryotic host cell. Suitable prokaryotic hosts include, for example, *E. coli*, such as *E. coli* HB101, *E. coli* W3110, *E. coli* DH1 α , *Pseudomonas*, *Bacillus*, such as *Bacillus subtilis* and *Streptomyces*. Suitable eukaryotic host cells include yeast and other fungi, insect, and animal cells such as CHO cells, COS cells and human cells and plant cells in tissue culture. Accordingly, the present invention provides a cell transfected with an expression

construct having an S30-21616/DEGA polynucleotide, e.g., SEQ ID NO:1 and SEQ ID NO:3, operatively linked to expression control sequences. Preferably, such a transfected cell expresses an S30-21616/DEGA polypeptide, e.g., SEQ ID NO:2 and SEQ ID NO:4.

[54] The polypeptides or variants or analogs and fragments thereof of the present invention may be purified by methods well known in the art. For example, the polypeptides or variants and fragments thereof may be expressed as cleavable fusion polypeptide with an appropriate fusion partner that facilitates purification and identification. Useful fusion partner polypeptides include, but are not limited to, histidine tags, glutathione S-transferase or GST, intein [IMPACT™ or Intein Mediated Purification with an Affinity Chitin-binding Tag from New England Biolabs, Beverly, MA; Chong et al. (2001) *Gene* 275:241:252], and β -galactosidase. The fusion polypeptide may be purified by affinity chromatography using an antibody column, such as an anti- β galactosidase antibody column if β -galactosidase fusion is used.

[55] The polypeptides or variants or analogs thereof in the present invention are useful for the discovery and isolation of one or more putative ligand(s), polypeptide- or DNA-binding partner(s). In another embodiment of the invention, these putative ligand or polypeptide-binding partner, or fragments thereof, may function as inhibitory (antagonist) or stimulatory (agonist) factors as well as in the design of biomolecules, such as, but not limited to, peptides or antigens and oligonucleotides, or small molecules that are active against S30-21616/DEGA polypeptide of diseased cells, such as, but not limited to, an antagonist. The present invention also provides an S30-21616/DEGA antagonist, which is an agent or compound that is capable of reducing the receptor or receptor-like activity of S30-21616/DEGA. The present invention also provides an S30-21616/DEGA agonist, which is a compound or agent that enhances a desirable pharmacological activity of S30-21616/DEGA.

[56] In a further embodiment of the present invention, these immunopharmaceuticals may be effective in inhibiting the expression, interaction and/or function of this cell surface molecule or its variant forms. These immunopharmaceuticals may be targeted to one or more regions of the polypeptide,

such as, but not limited to, the immunoglobulin (Ig)-like domain or LRR of the polypeptide or its signaling pathways represented by, e.g., the polypeptide kinase C, casein kinase II phosphorylation sites, or other phosphorylation sites.

[57] Ligands or small molecules such as an agonist or antagonist that bind to the S30-21616/DEGA polypeptide in the invention can be obtained by any suitable method. As is appreciated by those of skill in the art, there are various such methods to screen for suitable small molecules, examples of, which are described below.

[58] Screening for compounds that bind to, e.g., a cell-line expressing S30-21616/DEGA polypeptide, can be used to identify suitable ligands or small molecules. One such method for screening involves contacting the cells with the compounds to be screened using a microarray type format and determining whether such compounds generate a signal, i.e. activation or inhibition of the polypeptide function, such as but not limited to, a change in signal transduction or pH. These changes are measured to determine if the compound activates or inhibits the polypeptide.

[59] Another method of screening for ligands or small molecules involves the use of the cell line that is loaded with an indicator dye. When bound to the test compound in the presence or absence of an ionic species, such as but not limited to, calcium, a fluorescent signal is produced. The change in fluorescent signal is measured over time using, for example, a fluorescent spectrophotometer or fluorescence imaging plate reader. The change in fluorescence indicates binding of ligand to target polypeptide and that the compound is a potential antagonist or agonist for the polypeptide.

[60] A further method of screening for ligands or small molecules involves the use of a cell line transfected with the polypeptide of the present invention and a reporter polynucleotide construct that is linked to the activation of the polypeptide. Examples of such reporter genes include but are not limited to β -galactosidase, green fluorescent polypeptide (GFP), chloramphenicol acetyltransferase (CAT), luciferase (LUC) and β glucuronidase. After the cells are contacted with the test compound and a known agonist, the signal produced by the reporter polynucleotide over a certain time period

can be measured using a fluorimeter, spectrophotometer, luminometer or some other instrument appropriate for the reporter polynucleotide used. A decrease in signal indicates that the compound inhibits the function of the polypeptide and hence is a potential antagonist of the polypeptide.

[61] Another method of screening for compounds that are antagonists, and therefore inhibit activation of the polypeptide, involves binding assays well known in studies on receptorology. Cells that express the polypeptide or receptor on the surface of the cell or cell membranes isolated from the cell thereof is contacted with potential antagonist in the presence of a known, labeled ligand. The ligand can be labeled with radionuclides or fluorescent molecules. The amount of labeled ligand bound is measured, i.e. by radioactivity or fluorescent associated with the cell or cell membrane. If the test compound binds to the polypeptide and a reduction of the labeled ligand binding to the receptor is measured, the compound is therefore capable of competing with the natural ligand and hence is a potential antagonist.

[62] Another embodiment of the invention relates to a method for generating or screening of antibodies, especially neutralizing or polypeptide-polypeptide interaction inhibiting antibodies specific for S30-21616/DEGA polypeptides and analogs thereof, antisense molecules, peptides or small molecules. Antibodies of the present invention include complete anti-S30-21616/DEGA antibodies, as well as antibody fragments and derivatives that comprise an S30-21616/DEGA binding site or the Ig domain and the LRR. Antibody fragments include, but are not limited to, Fab, F(ab')₂, Fv and scFv, dibody or single domain antibody. In another embodiment of the invention, antibodies and fragments thereof to the polypeptide receptor or variants thereof can be selected by phage display library well known in the art (See, e.g., McCafferty et al., (1990) *Nature* 348:552-554; Aujame et al., (1997) *Hum. Antibodies* 8:155-168). Combinations of variable domains are typically displayed on filamentous phage in the form of Fab's or scFvs. The library is screened for phage bearing combinations of variable domains having desired antigen-binding characteristics. Preferred variable domain combinations are characterized by high affinity for S30-21616/DEGA. Preferred variable domain combinations can also be characterized by high specificity for S30-21616/DEGA and has little cross-reactivity to other related antigens. By screening from very large repertoires of antibody fragments, (2-10x10¹⁰; see e.g.,

Griffiths et al., (1994) *EMBO* 13:3245-3260) a good diversity of high affinity monoclonal antibodies can be isolated, with many expected to have sub-nanomolar affinities for S30-21616/DEGA.

[63] The antibody of the present invention may be a monoclonal (MAb) or polyclonal antibody derived from rodents, human or humanized or chimeric antibodies. The major drawback of rodent MAbs is that, although they may be administered to a patient for diagnostic or therapeutic purposes, they are recognized as foreign antigens by the immune system and are unsuitable for continued use. Antibodies that are not recognized as foreign antigens by the human immune system have greater potential for both diagnosis and treatment. Human antibodies are antibodies that consist essentially of human sequences and can be obtained by phage display libraries where combinations of human heavy and light chain variable domains are displayed on the phage surface. Methods for generating human and humanized antibodies are now well known in the art. For a review of antibody humanization and of the nomenclature applied to antibody domains and regions, see, e.g., Vaughan et al. (1998) *Nat. Biotechnol.* 16:535-539

[64] Chimeric antibodies can be constructed in which regions of a non-human MAb are replaced by their human counterparts. A preferred chimeric antibody is one having the whole variable regions of a non-human antibody such as a mouse or rat variable region expressed along with the human constant region. Methods for producing such antibodies are well known in the art (See, e.g., Jones et al., (1996) *Nature* 321:522-525; Riechman et al., (1988) *Nature* 332:323-327, U.S. Patent 5,530,101 and Queen et al (1989) *Proc. Natl. Acad. Sci.* 86:10029-10033). A more preferred chimeric antibody of the invention is a humanized antibody. A humanized antibody is an antibody in which the complementarity determining region (CDR) of the non-human antibody V-region that binds to, for example, hS30-21616/DEGA, is grafted to the human framework (FW) region (Padlan, (1991) *Mol. Immunol.* 28:489-498). Amino acid residues corresponding to CDRs and FWs are known to one of skill in the art. Chimeric antibodies can also include antibodies where some or all non-human constant domains have been replaced with human counterparts (see, e.g., LoBuglio et al., (1989) *Proc. Natl. Acad. Sci.* 86:4220-4224).

[65] In a preferred embodiment of the invention, a therapeutic method for prevention, treatment, or amelioration of a medical condition is disclosed. In this method, the newly isolated antibody, human or humanized antibody and fragments thereof, can be conjugated to a radioisotope such as, but not limited to, Yttrium-90, a cytotoxic or chemotherapeutic agent. The conjugated antibody or fragments thereof can be administered to the patient by injecting in the patient after surgery or chemotherapy an effective amount that is capable of destroying micrometastasis or delaying or preventing recurrence of disease. The antibody and fragments thereof also can be used as a method for diagnosing tumor in the cells of a patient such as a human or an animal.

[66] The antibodies of the present invention are also useful for detecting the present polypeptides and polypeptides in specific tissues or in body fluids. Immunoassays may use a monoclonal or polyclonal antibody reagent that is directed against one epitope of the antigen being assayed. Alternatively, a combination of monoclonal or polyclonal antibodies may be used which are directed against more than one epitope. Protocols may be based, for example, upon competition, direct antigen-antibody reaction or sandwich type assays. Protocols may, for example, use solid supports or immunoprecipitation. The present antibodies can be labeled with a reporter molecule for easy detection. Assays that amplify the signal from a bound reagent are also known. Examples include immunoassays that utilize avidin and biotin or enzyme-labeled antibody or antigen conjugates, such as ELISA assays.

[67] In another preferred embodiment of the invention, a method for eliciting and stimulating an immune response in a human subject in whom prevention, treatment or amelioration of a neoplastic disease is provided. The method includes administering to the subject a composition having an antigenic molecule that is capable of eliciting an immune response, such as an antibody response, and more preferably a cellular immune response. The "antigenic molecule" used herein is a peptide or fragment of a polypeptide that is identified using standard immunoassays known in the art by detecting the ability of said peptide or polypeptide fragment to bind to antibody or MHC molecules (antigenicity) and generate an immune response (immunogenicity). In one aspect, any of the antibodies disclosed herein can be used to elicit and stimulate an immune response, e.g., resulting in death of a cell expressing the S30-

21616/DEGA polypeptide. It is further appreciated that the antigenic molecule can be administered as a polynucleotide that is subsequently translated into the antigenic polypeptide *in vivo*. It is also further appreciated that the antigenic molecule is an immunogen having a peptide of at least 8 amino acids.

[68] Any suitable neoplastic disease, i.e., cancer, can be treated using the present inventive methods, including, e.g., stomach, thyroid, breast, ovarian, kidney, or lung cancers.

[69] The antigenic molecule of the therapeutic composition can be administered in a pharmaceutically acceptable carrier or in a non-covalent complex with another polypeptide in the presence or absence of immuno-enhancers or biological response modifiers, including but not limited to, the cytokines such as but not limited to interferons, (IFN- α , IFN γ), interleukins, (IL-2, IL-4, IL-6) or tumor necrosis factors (TNF- α , TNF- β).

[70] Another embodiment of the invention for enhancing an immune response in a human comprises administering to the human subject antigen presenting cells (APCs) sensitized *in vitro* with the antigenic molecule. The APC can be selected from among those antigen presenting cells known in the art, including but not limited to B lymphocytes, dendritic cells, macrophages, T lymphocytes and combination thereof and preferably macrophages and more preferably, dendritic cells.

[71] The polynucleotides of the present invention can be used in the treatment of metastatic cancer. Treatments include polynucleotide ablation, polynucleotide replacement, polynucleotide expression and antisense polynucleotide suppression. In a preferred embodiment of the invention, the method of treatment of a metastatic cancer, involves administering a pharmaceutical composition containing an effective amount of an S30-21616/DEGA polynucleotide, or fragment thereof, with additional sequences such as promoters for expression of sense and antisense message, recombinant sequences for targeting the gene, selectable markers for transfection and selection or replication or origins for passage in a prokaryotic, eukaryotic, bacteria, insect or yeast cells. The nucleic acids used may be single or double stranded DNA, RNA or PNA. The variants of the nucleic acids may include alterations such as

deletion, substitution, addition or non-conservative alterations found naturally or engineered.

[72] It is understood that antibodies and antibody conjugates, polynucleotides and fragments, polypeptide and analogs of the invention, small molecules including agonist and antagonist, where used in the human body for the purpose of diagnosis or treatment, will be administered in the form of a composition additionally having a pharmaceutically-acceptable carrier. Such carriers are well known to one of average skill in the art. Modes of administration include, but are not limited to, subcutaneous, intramuscular, intravenous, intraperitoneal, intradermal or mucosal routes.

[73] Human S30-21616/DEGA polynucleotides and polypeptides of this invention are differentially expressed in hematopoietic stem cells (see *Example 2*) and may be useful in the regulation of hematopoiesis. Consequently, the S30-21616/DEGA polynucleotides and polypeptides of this invention, or agents directed against such polynucleotides and polypeptides, may be useful for the treatment of stem cell associated diseases, and in particular disease of hematopoiesis such as myeloid and lymphoid cell deficiencies, for example, leukemia or in supporting the growth and proliferation of erythroid progenitor stem cells. Agonist and antagonist of the polypeptide in this invention are also envisioned in treatment of stem cell associated diseases.

[74] Another embodiment of the invention may be directed to the use of the nucleic acid or polypeptide as marker for stem cell isolation, and in particular in hematopoietic stem cell isolation for use in transplantation. Since hematopoietic stem cells are capable of maturing to various different hematopoietic cells, such as erythroid, myeloid and lymphoid cells. These isolated stems cells may be useful for, but not limited to, repopulation of the stem cells after radiation or chemotherapy, in *in-vivo* or *ex-vivo* bone marrow transplantation.

[75] The S30-21616/DEGA polynucleotides and polypeptides of the present invention can be administered alone or in combination with other cytokines in a pharmaceutically acceptable composition for treatment of, but not limited to, various anemias or for the use in conjunction with irradiation or chemotherapy to stimulate

the production of precursors or erythroid cells; in supporting growth and proliferation of myeloid cells, such as monocytes, macrophages and megakaryocytes; and supporting growth and proliferation of hematopoietic stem cells. In another embodiment of the invention, inhibitory molecules may be used to alter hematopoietic stem cell interacting with supporting stromal cells.

[76] Accordingly, the present invention can be used *in vivo* and *in vitro* for investigative, diagnostic, prophylactic, or treatment methods, which are well known in the art. The examples that follow further illustrate the invention, but should not be construed to limit the scope of the invention in any way. Other embodiments and uses of the invention will be obvious to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. Detailed descriptions of conventional methods, such as those employed in the construction of vectors and plasmids, the insertion of genes encoding polypeptides into such vectors and plasmids, the introduction of plasmids into host cells, and the expression and determination thereof of genes and polynucleotide products, can be obtained from numerous publication, including Sambrook, J. et al., (1989) *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press. All references mentioned herein are incorporated in their entirety.

EXAMPLES

Cell Cultures

[77] Cell lines used were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and media used for their propagation were purchased from Gibco, Grand Island, NY. Cell lines and their respective growth media (shown in parentheses) were as follow: AGS, a human gastric adenocarcinoma cell line, (F-12); 293, a human kidney epithelial cell line transformed with adenovirus 5 DNA, (Dulbecco's Modified Eagles Medium (DMEM)); KKVR (Iscove's DMEM); RF-1, a human gastric adenocarcinoma cell line, (Leibovitz's L-15); NCI-SNU-1, NCI-SNU-16, NCI-N87, a human liver gastric carcinoma cell line and KatoIII, a human gastric carcinoma, (RPMI). All media were supplemented with 2 mM L-Glutamine (Gibco, Grand Island, NY) and 10% Fetal Bovine Serum (FBS; Hyclone, Logan, UT).

KatoIII and KKVR, however, were grown in 20% FBS and NCI-N87 and KKVR growth media were additionally supplemented with 1.5 g/L sodium bicarbonate.

Example 1

[78] The present example demonstrates identification of differentially expressed novel cancer genes. Briefly, a murine hematopoietic stem cell subtractive cDNA library was utilized. Phillips et al. (2000) *Science* 288:1635-1640. Approximately 7,500 ESTs from this library were placed on DNA microarrays and hybridized with cDNA prepared from a variety of murine cancer cell lines and corresponding normal tissue.

[79] One of the murine ESTs, S30-21616/DEGA, was identified as being 7.6 fold differentially expressed in the murine renal cell line, RAG versus normal renal tissue. This EST was sequenced and its 522 bps used to blast the NCBI non-redundant sequence databases. At this time, S30-21616/DEGA showed no homology to any known murine sequences. It did, however, show approximately 85% similarity to human chromosome 12 BAC clones and to a portion of a human endometrial cancer partial cDNA clone (IMAGE: 3625286). The IMAGE: 3625286 DNA sequence was used to generate 5' RACE ORF, and 3' UTR PCR products to give a final cDNA (*hS30-21616/DEGA*) of 3769 bp (Figure 1). Transcription of the cDNA resulted in various size transcripts of 2.2 and 3.5 KB, implying alternative splicing.

Example 2

[80] The present example demonstrates expression of *hS30-21616/DEGA* in normal and cancer tissues. Briefly, Northern blot analyses using multiple tissue Northern (BD Biosciences/Clontech, Palo Alto, CA) were performed to assess the expression of *hS30-21616/DEGA* in normal and cancer tissues. The normal tissues screened include brain, heart, skeletal muscle, colon, thymus, spleen, kidney, liver, small intestine, placenta, lung, peripheral blood leukocyte, adrenal gland, bladder, bone marrow, lymph node, prostate, spinal cord, stomach, thyroid, trachea, uterus, and tongue. In a majority of these tissues, expression of *hS30-21616/DEGA* was very low.

[81] With respect to cancer cell line expression, we assessed *hS30-21616/DEGA* expression by Northern blot analysis in HL-60 (Promyelocytic Leukemia), HeLa (Cervical Carcinoma), K562 (Chronic Myeloid Leukemia), Molt-4 (Acute Lymphoblastic Leukemia), Raji and Daudi (Burkitt's Lymphoma), SW480 (Colorectal Adenocarcinoma), G361 (Melanoma), A549 (Lung Carcinoma) cells, AGS (human gastric adenocarcinoma), NCI-SNU-1, NCI-SNU_16, and NCI-N87 (human liver gastric carcinoma).

[82] *Human S30-21616/DEGA* was expressed as multiple sized transcripts of 2-3.5 KB in A549 (data not shown) as well as in AGS and NCI-SNU-16 (see, Figure 3 PLEASE CHECK, SEE BELOW) cells. These size transcripts are also observed in GenBank® cDNAs expressed in testis, stomach, lung and uterus. Due to its differential expression profile in gastric adenocarcinoma, S30-21616 cDNA is henceforth named *S30-21616/DEGA*.

Example 3

[83] The present example demonstrates Cancer Profiling Array (CPA) analysis of S30-21616/DEGA expression in patient samples using cDNA dot blots. Briefly, in a variety of tumor and normal tissues (CPA) I and II (BD Biosciences Clontech, Palo Alto, CA) were probed with a cDNA fragment encompassing ORF nucleotides 1540-2045 (numbering based on Figure 1) as per manufacturer's recommendations. The probe was labeled using [α - 32 P]-dCTP (PerkinElmer Life Sciences, Inc, Boston, MA) and isolated using the Prime-It® II kit (Stratagene Cloning Systems, La Jolla, CA). CPA I and II are nylon arrays containing normalized cDNA from 241 and 160 tumor and corresponding normal tissues obtained from individual cancer patients respectively. Tissues represented by CPA I include: breast, uterus, colon, stomach, ovary, lung, kidney, rectum, thyroid, cervix, small intestine, pancreas and prostate. In addition to these tissues, CPA II carries bladder, testis, and skin tissue. These arrays also contain positive and negative controls as well as cDNA isolated from nine cancer cell lines: HeLa, Daudi, K-562, HL-60, G-361, A549, Molt-4, SW480 and Raji.

[84] The results from the array profile in Figures 2A (CPA I) and 2B (CPA II) again showed that DEGA was expressed in some normal lung, colon and rectum

samples but the expression are generally lower than in the female reproductive tissues. Nearly every patient showed strong expression of DEGA in normal breast tissues. In contrast, DEGA expression in tumor samples was differentially expressed in 56% of thyroid (9/16; 5/6 in CPA I, and 4/10 in CPA II) and 45% of stomach cancers (17/38; 14/28 in CPA I and 3/10 in CPA II). Of the cancer cell lines tested in CPA I (Figure 2A) and CPA II (Figure 2B), A549 expressed high levels of DEGA cDNA and K562 expressing approximately 10 fold less DEGA cDNA than A549 cells. There was minimal expression in Molt-4, G361 and HeLa cells.

[85] Table 1 further provides a summary of the regulated differential expression of DEGA from various tissues using the arrays. The expression levels were normalized against cDNA from 241 tumor and corresponding normal tissues from individual patients.

TABLE 1.

Type of Cancer	Number of Samples	Up Regulated	Down Regulated	No Difference
Stomach	28	45%	34%	21%
Thyroid	6	83%	0%	17%
Breast	50	6%	70%	24%
Ovary	14	0%	43%	57%
Lung	21	19%	57%	24%
Uterus	42	19%	26%	55%
Colon	34	26%	26%	48%
Cervix	1	0%	0%	100%
Kidney	20	10%	10%	80%
Rectum	18	11%	11%	78%
Prostate	4	0%	50%	50%
Pancreas	1	0%	0%	100%
Small Intestine	2	0%	0%	100%

[86] In twenty-eight of the stomach and six thyroid cancers profiled, *hS30-21616/DEGA* was up-regulated in 45% and 83% of tumor respectively versus normal samples. However, in fifty breast, fourteen ovarian, and twenty one lung cancers typed, *hS30-21616/DEGA* was down-regulated in 70%, 43% and 57% of tumor

respectively versus normal samples. The results showed that *hS30-21616/DEGA* is differentially expressed in different tumor types and may play a role in modulating tumor growth.

Example 4

[87] The present example demonstrates Northern Blot analysis of DEGA expression in gastric adenocarcinoma cells. The observation that 45% of the stomach cancer patient samples showed differential expression of DEGA in their tumors but insignificant expression in adjacent normal stomach tissue suggests that DEGA may play a pivotal role in the development or progression of at least a sub-fraction of gastric adenocarcinoma. Northern Blot analysis was carried out to determine whether DEGA was expressed in the adenocarcinoma cell lines, AGS, NCI-SNU-1, NCI-SNU-16, NCI-N87, KATOIII, KKVR and RF-1.

[88] The autoradiograph in Figure 3 shows that expression in both AGS (Lane A) and NCI-SNU-16 (Lane F) cells, with AGS having eight-fold greater expression over NCI-SNU-16.

Example 5

[89] The present example demonstrates Cancer Profiling Array (CPA) analysis of S30-21616/DEGA expression in other non-gastric adenocarcinoma cancer cell lines. Using cDNA dot blots, the *S30-21616/DEGA* probe and conditions used for CPA I and II were also used to hybridize BD Bioscience's Cancer Cell Line Profiling Array, which contains cDNA from cell lines representing cancer of the lung (A549, NCI-H-460, NCI-H1299), colon (HCT-116, HCT-15, HT-29), breast (MDA-MB4355, MDA-MB231, MCF7), ovary (SK-OV-3), cervix (HeLa), prostate (DU-145, PC-3), skin (SK-MEL-28, SK-MEL-5, SK-NSH, IMR-32, U-87MG), brain (IMR-32, U-87MG), kidney (786-O, ACHN), liver (Hep-G2), colon (Colo589), osteosarcoma (U2-OS), and epidermis (A-431).

[90] The results showed that the highest expression was observed in lung NCI-H1299 and A549 cells (Figure 4, left panel), kidney ACHN cells and U2-OS

osteosarcoma cells (Figure 4, right panel). Lower but significant expression was observed in renal line, 786-O (Figure 4, right panel), MDA-MB-231 breast cells and ovarian cancer cell line, SKOV-3 (Figure 4, left panel).

Example 6

[91] The present example demonstrates S30-21616/DEGA cDNA cloning. Briefly, Human S30-21616/DEGA cDNA was amplified as a RT-PCR product derived from Marathon-Ready™ A549, a human lung cell carcinoma line and spleen cDNA preparations (BD Biosciences/Clontech, Palo Alto, CA). The PCR primers used to amplify the polynucleotide of interest are forward PCR Primer No. 1 with the sequence 5' ATG TCG TTA CGT GTA CAC ACT CTG 3' (SEQ ID NO:14) and reverse PCR Primer No. 2, 5' TTA AGT GGA CGC CAC AAA AGG TGT G 3' (SEQ ID NO:15) (Bio-Synthesis Incorporated, Lewisville, TX; start and stop codons are underlined). The PCR reaction was performed using standard RT-PCR protocols well known in the art, with the exception of the polymerase used, which is Titanium Taq polymerase (BD Biosciences/Clontech, Palo Alto, CA), specifically the RT-PCR condition described in the Marathon-Ready™ cDNA manual was utilized: 94°C, 30 seconds; 68°C, 2 minutes.

[92] The S30-21616/DEGA ORF PCR product (1569 bp) was cloned into pCR2.1 (Invitrogen Corporation, TOPO TA® Cloning Kit, Carlsbad, CA) and sequence verified (Molecular Genetics Instrumentation Facility, University of Georgia, Athens, GA; GENEWIZ Inc, North Brunswick, NJ). To obtain DNA sequence upstream of the S30-21616/DEGA start codon; 5' RACE was performed using A549 Marathon-Ready™ cDNA as explained above with few modifications. AP1, a forward primer (included with the Marathon-Ready™ cDNA) and a S30-21616/DEGA gene-specific reverse primer (5' AAC TCA GGT CCA GTC TCT TAA TCA G 3'; SEQ ID NO:16) produced a PCR product after 35 rounds of amplification (94°C, 30s; 57°C, 30 sec; 68°C, 2 min.) that was sub-cloned into pCR2.1 and sequenced verified. Sequence representing the 3' UTR of S30-21616/DEGA was initially obtained computationally from the human chromosome 12 BAC clone, GS1-99H8 (GenBank® accession #AC004010). A series of PCR primers were subsequently designed to determine the longest 3' UTR sequence present in the A549 cDNA preparation. The following

primer set was used to identify the longest 3' UTR segment: forward primer 5' ATG TCG TTA CGT GTA CAC ACT CTG 3' (SEQ ID NO:17); start codon underlined and reverse primer 5' CAA AAT GAA AAG ACA GGC AAA CAA ATG 3' (SEQ ID NO:18), which initiates at X nucleotides 3' of the *S30-21616/DEGA* ORF.

[93] Figure 5A schematically shows the structural features of the gene product of *S30-21616/DEGA*. The protein possesses a signal sequence and a transmembrane domain suggesting that it may localize to the cell surface. Its putative extracellular portion contains an Ig domain and 5 leucine-rich repeats (LRR) flanked by cysteine residues present in LRR-N-terminal (LRR-NT) and LRR-C-terminal (LRR-CT) domains. Consequently, *S30-21616/DEGA* appears to belong to the LRR superfamily. The putative cytosolic portion of *S30-21616/DEGA* contains 102 amino acids and lacks the presence of any known protein domains. Approximately 1/5 or 20 of the cytosolic residues are either a serine or a threonine, suggesting that *S30-21616/DEGA* may function as a signaling molecule in the cell. Taken together, protein sequence analysis suggests that the *S30-21616/DEGA* gene product may function as a signaling cell adhesion molecule. The corresponding amino acid sequence of the protein is illustrated in Figure 5B.

Example 7

[94] The present example demonstrates stable expression of an *S30-21616/DEGA*-EGFP fusion construct in 293 cells and sub-cellular localization of the protein. Briefly, a fusion protein was engineered whereby an enhanced green fluorescent protein (EGFP) was fused to its C-terminus. The *S30-21616/DEGA* ORF was PCR amplified and cloned into XhoI/AgeI sites of pEGFP-N1 (BD Biosciences Clontech, Palo Alto, CA). The PCR reaction was performed as described in the *S30-21616/DEGA* cDNA cloning section with the exception that the forward primer used (5' ATC CTC GAG GCG ACC ATA ATG TCG TTA CGT GTA CAC ACT 3'; SEQ ID NO:19), which contained the native Kozak sequence and a Xho I site (underlined) 5' to the start codon shown in bold. The reverse primer used (5' GAT CAC CGG TGC AGT GGA CGC CAC AAA AGG TGT GTC 3'; SEQ ID NO:20) contained an Age I site (underlined) 3' of the stop codon shown in bold.

[95] The *S30-21616/DEGA-EGFP* construct was stably transfected into 293 cells using FuGENE6 transfection reagent (Roche Molecular Biochemicals, Indianapolis, IN) as outlined by the manufacturer. A 2:1 FuGENE6:DNA ratio was used. Transfected cells were left for 2 days at 37°C after which time they were plated in limiting dilution and subjected to selection with 800 µg/ml Geneticin (Sigma-Aldrich Corp., St. Louis, MO). Individual clones were isolated by trypsinization using cloning rings and allowed to expand.

[96] To determine the sub-cellular localization of the *S30-21616/DEGA-EGFP* fusion protein, clones were assessed using a Zeiss Axioskop fluorescent microscope (200x magnification). The fluorescent micrograph shown in Figure 7 confirmed cell surface localization of the *S30-21616/DEGA* protein.

Example 8

[97] The present example demonstrates stable expression of *S30-21616/DEGA* antisense constructs in AGS cells. The expression profile of *S30-21616/DEGA* suggests that it may play a functional role in the development or progression of a subset of human gastric adenocarcinoma. To address the functional role of *S30-21616/DEGA*, human AGS cell line that has been shown to express significant levels of *S30-21616/DEGA* mRNA was transfected to stably express antisense *S30-21616/DEGA* construct or an empty vector. The cells lines established were used in comparison studies of clones in cell cycle, proliferation and tumorigenicity assays.

[98] To generate *S30-21616/DEGA* antisense clones, a nucleotide fragment encompassing the entire ORF of *S30-21616/DEGA* as well as one that comprised the 5' most 608 nucleotides of its ORF (generated from a partial Eco-RI digest of pCR2.1-*S30-21616/DEGA*) were cloned into pIRES PURO2 (BD Biosciences Clontech, Palo Alto, CA) in reverse orientation and stably transfected into AGS cells. Concurrently, pIRES PURO2 was also stably transfected into these cells to serve as an empty vector control. Transfection and clone isolation were performed exactly as described for the *S30-21616/DEGA-EGFP* fusion with the exception that cells were selected with 400 µg/ml puromycin (Sigma-Aldrich Corp., St. Louis, MO).

Example 9

[99] The present example demonstrates comparative expression of AGS/DEGA antisense and empty vector clones by Northern Blot analysis. To determine the effect of *S30-21616/DEGA* expression in gastric adenocarcinoma cell line, AGS stably transfected with antisense *S30-21616/DEGA* and empty vector, standard Northern blotting procedures were carried out. Total RNA was isolated using the Micro-to-Midi Total RNA system (Invitrogen Corporation, Carlsbad, CA) exactly as recommended by the manufacturer and 5 µg was resolved on a 1.2% denaturing formaldehyde gel and transferred to Nytran[®] SuperCharge membranes (Schleicher & Schuell, Inc., Keene, NH). Blots were hybridized with the ³²P random-labeled *S30-21616/DEGA* C-terminal probe used to probe the CPA I and II cDNA blots. Hybridizations were performed for one hour at 68°C using ExpressHyb[™] solution (BD Biosciences Clontech, Palo Alto, CA). Three 10 minute room temperature washes (2 X SSC, 0.05% SDS) and two 20 minute 50°C washes (0.1 X SSC, 0.1% SDS) followed. Membranes were rinsed in 2 X SSC and exposed overnight at -70°C to Kodak BioMax MR film. (Eastman Kodak Company, Rochester, NY.)

[100] Northern blot analysis of AGS/DEGA antisense clones showed significant and stable down-regulation of *S30-21616/DEGA* expression. Figure 8 shows a decreased level of mRNA expression for AGS/DEGA antisense clone #6 (lane 3) and clone #11 (lane 4) compared to untransfected or wild type (WT) AGS parental cells (lane 1) and AGS empty vector clone #15 (lane 2). The lower panel shows the mRNA expression of β -actin in the cells tested as controls.

Example 10

[101] The present example demonstrates DNA content/cell cycle profiles of AGS/DEGA antisense clones and empty vector clones by flow cytometry analysis. To measure DNA content and therefore cell cycle profile, flow cytometry was utilized. AGS empty vector and *S30-21616/DEGA* antisense clones were grown asynchronously in serum-containing growth media, trypsinized, washed once in PBS and stained for 10 minutes at room temperature in the dark with the propidium iodide solution provided in the DNA QC Particles kit (Catalog # 349523; Becton Dickinson).

Cells were subsequently analyzed on a Becton Dickinson FACSVantage™ flow cytometer using parameters outlined in the DNA QC particles kit. Cell size was assessed by light microscopy.

[102] Flow cytometric analysis of the propidium iodide stained cells showed that AGS/empty vector cells demonstrated a typical DNA content/cell cycle phase profile for proliferating cells, with a majority of cells in G₀/G₁, followed in quantity by cells in G₂/M and S phase (*see*, Figure 9, left panel, top histogram). In contrast AGS/DEGA antisenseclones #6 (*see*, Figure 9, left panel, middle histogram) and #11 (*see*, Figure 9, left panel, bottom histogram) displayed a dramatic alteration in the cell cycle profile. Nearly all cells displayed a shift towards the G₂/M phase of the cell cycle. Clone #11 showed slightly greater shift towards the G₂/M phase than clone #6. The shift to G₂/M also correlated to the increase in cell size observed for both AGS/DEGA antisenseclone #6 and #11 (*see*, Figure 9, bottom two right panel) in contrast to the cell size observed for AGS/empty vector cells (*see*, Figure 9, top right panel).

Example 11

[103] The present example demonstrates in-vivo tumorigenicity studies of DEGA-expressing cells. Given the cell cycle profile differences observed between AGS/empty vector and AGS/DEGA antisenseclones, a difference in cell proliferation *in vivo* is also expected. Since AGS cells are tumorigenic in nude mice, the effect of S30-21616/DEGA antisensein suppressing S30-21616/DEGA expression and hence negatively influence the tumorigenic potential of AGS cells was carried out as follows. AGS clones were suspended in growth media, placed on ice and thoroughly mixed with MATRIGEL™ (Collaborative Research Biochemicals, Bedford, MA) at a 1:1 (v/v) ratio. MATRIGEL™ is derived from the Engelbroth-Holm-Swarm mouse sarcoma, which has been found to be a rich source of the ECM proteins: laminin, collagen IV, nidogen/enactin and proteoglycan (12). When mixed with cell lines, MATRIGEL™ enhances tumorigenesis (27). For each athymic (nu/nu) mouse (Charles River Laboratories, Wilmington, MA), ten million cells were injected subcutaneously and tumor volumes (mm³) were measured weekly using calipers for 11 weeks.

[104] Figure 10 depicts the results of tumor growth study in mice. After 75 days, 12/12 AGS cell-injected mice and 19/19 AGS/empty vector clone #15 injected mice developed tumor with a mean tumor volume of approximately 800 mm³. In sharp contrast, only 6/12 mice injected with AGS/DEGA antisenseclone #6 and 6/19 mice injected with AGS/DEGA antisenseclone #11 developed tumors with a mean tumor volume of approximately 20 mm³.

What is claimed is:

1. A purified nucleic acid molecule comprising a nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3, or a fragment thereof.
2. A purified nucleic acid molecule comprising a sequence at least 80% identical to SEQ ID NO:1 or SEQ ID NO:3.
3. The purified nucleic acid molecule of claim 1, wherein the nucleotide sequence is a degenerate variant of SEQ ID NO:1 or SEQ ID NO:3.
4. The purified nucleic acid of claim 1 comprising a sequence that hybridizes under highly stringent conditions to a hybridization probe, wherein the nucleotide sequence consist of SEQ ID NO:1 or SEQ ID NO:3; or the complement thereof.
5. A purified nucleic acid of claim 1, comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, or of a fragment of at least 8 residues in length.
6. The purified nucleic acid of claim 6, wherein the nucleotide sequence encodes a polypeptide comprising amino acid sequence variants of SEQ ID NO:2 or SEQ ID NO:4.
7. A purified nucleic acid molecule comprising a sequence complementary to a portion of the nucleic acid molecule of claim 1.
8. A purified antisense oligonucleotide that inhibits the transcription of a polynucleotide of SEQ ID NO:1 or SEQ ID NO:3 in a cell.
9. The purified antisense oligonucleotide of claim 8, wherein the oligonucleotide comprises a portion of an ORF of SEQ ID NO:1 or SEQ ID NO:3.

10. The purified antisense oligonucleotide of claim 8, wherein the oligonucleotide comprises a portion of nucleotides 1-608 of an ORF of SEQ ID NO:1 or SEQ ID NO:3.

11. The purified antisense oligonucleotide of claim 7, wherein the oligonucleotide comprises 20-30 nucleotides

12. An expression vector comprising the nucleic acid sequences as in any one of claims 1-10, operably linked to an expression control sequence that directs production of a transcript that hybridizes under physiological conditions to SEQ ID NO:1 or SEQ ID NO:3.

13. A recombinant host cell comprising the vector of claim 11.

14. A recombinant cell transfected with the vector of claim 11, or a progeny of the cultured cell, wherein the cell expresses the polypeptide.

15. A method of producing a polypeptide, wherein the method comprises culturing the cell of claim 13 under conditions permitting expression, and purifying the polypeptide from the cell or the medium of the cell.

16. A method of decreasing expression of a polypeptide of claim 6 in a diseased cell comprising:

- (i) providing an oligonucleotide comprising a sequence of SEQ ID NO: 1 or SEQ ID NO:3;
- (ii) providing a human cell comprising an mRNA encoding a polypeptide of SEQ ID NO:2; and
- (iii) introducing the oligonucleotide into the cell, wherein the oligonucleotide decreases expression of the polypeptide in the cell.

17. An isolated or purified antibody, or fragment thereof, that selectively binds to an epitope in the receptor-binding domain of a polypeptide of claim 6.

18. An isolated or purified antibody, or fragment thereof of claim 16, wherein the antibody further comprises an epitope that selectively inhibits polypeptide-polypeptide, cell-cell or cell-matrix interaction.
19. An isolated or purified polynucleotide encoding the antibody, or fragment thereof, as in claim 16 or 17.
20. An expression vector comprising the polynucleotide sequence in claim 18.
21. A recombinant host cell comprising the expression vector of claim 19.
22. The recombinant host cell of claim 20, or a progeny thereof, wherein the host cell expresses the antibody, or fragment thereof.
23. A method of producing a recombinant host cell comprising transfecting a cell with the expression vector of claim 20.
24. A method of producing an antibody, or fragment thereof, comprising culturing the cell of claim 22 under conditions permitting expression of the antibody or fragment thereof.
25. The method of claim 23, wherein the method further comprises isolating or purifying the antibody, or fragment thereof, from the cell or from the medium of the cell.
26. A method for treating tumor growth in a mammal in need thereof, comprising administering the mammal with an antisenseoligonucleotide, an antibody, or a fragment thereof.
27. The method of claim 25, further comprising treating the mammal selected from the group consisting of a receptor antagonist or agonist, an anti-neoplastic agent, radiation or a combination thereof.

28. The receptor antagonist or agonist of claim 26, wherein the antagonist or agonist is selected from a group consisting of an antibody specific for the protein of SEQ ID NO2 or SEQ ID NO:4, an antibody specific for another receptor and a small molecule.

29. A method of claim 25 for treating tumor growth in a mammal in need thereof, wherein the tumor is gastric adenocarcinoma.

Figure 1:

A)

GGGTCCTG CAGCCTCC CGAGTCGGGAGAGCGGGGCG CGCCGCTGCGCCCGCTGCTGCGCCCTCTCCGCGCCCGCTCTGGGAGCGGGCGCC 102
 CGCGCGCGG CACACGGCGCCAGAGCGCCGAGCGGTACCTT CAGCCTGCAATGAGAGGAAACCCGGAGAGCCCGGAGCCAGCGAAAGAGCTTGGCTGCT 204
 CGGTCCAGCGCTGCTGCTGCGCCGCGCTGCTTGAACCTCTCTAAAGTTGAGAGCCGGCTAGAGGCTGCGCCCGCGGGAGCGCGAGGAAAGAGAGTGG 306
 GGAGGTGCAAGAGTGACAGACAGGACAGACGAGCGAGACCTTCGGAGGCACTGCTAGGAGCTTCCCGCGAGCGCCAGAGGCTCCCGAGCACTGCTT 408
 CACTGGTGGAGGCTGAGCGCGTGGAAAGACACCGGGAAGAGACTCAGAGGAGACCAATATGCTGCTTACGCTGACACACTTCCACCTGCTTGGAGCC 510
 M S L R V H T L P T L L G A 14
 GTGTCAGACCGGGCTG CAGGAGCTGCTGTGTTTGTGTATGAT CACAGTGACTGTGGGCCCCTGGTGGCTCTCTGGGCTGCTGCTCCACCTGCTGCTGCT 612
 V V R P G C R E L L C L L M I T V T V G P G A S G V C P T A C I C A 48
 ACTGACATGCTGAGCTG CACCAACAAAACTCTG CCAAGGTGCTGCGAACCTTTT CAGACTGATTAAAGAGATGGAACCTGAGTTATACAGAAATGGGCTT 714
 T D I V S C T (N) K N L S K V P G N L F R L I K R L D L S Y N R I G L 82
 CTGGATTCTGAGTGGATTCCAGTATCGTTTGCAGAGCTGAACACCTAACTTCTGCTATACCAATCACCAGCAATTTCCAGGGAGCTTTTCCAACT. 816
 L D S E W I P V S P A K L N T L I L R H N (N) I T S I S T G S F S T T 116
 CCAATTTGAAGTCTCTGACTTATCTTCAATAAGCTGAAGACGGTCAAAATGCTGATTTCCAAGAGTTGAAGGTCTTGAAGTCTCTGCTTTACAA 918
 P N L K C L D L S S N K L K T V K N A V F Q E L K V L B V L L Y N 150
 AATCACAATCTCTGATCTCTGAGCTTTCAGCGTTTGGAGGCTCTCTCCAGTTCAGAGAACTCTACTTAAGTGGAAATTTTCTCA CACAGCTTTCCGATGGATTG 1020
 N H I S Y L D P S A P G G L S Q L O K L Y L S G N P L T O P P M D L 184
 TATGTTGGAAGGTTCAAGCTGGCAGAACTGATGTTTTAGATGTTTCTTATAACGAAATCTCTTCCAATGCAACACATAAATTTAGTCCAGGAAAA 1122
 Y V G R P K L A E L H F L D V S Y N R I P S M P M H H I N L V P G K 218
 CAGCTGAGAGGCTCTACCTTCTATGAAACCCATTTGCTGTGACTGTTCCCTGCTGCTGCTTTTGGTATCTGAGGCACTTTAGCTCAGTGATG 1224
 Q L R G I Y L H G N P F V C D C S L Y S L L V P W Y R R H P S S V M 252
 CATTTTAAGAAAGATTACCTCTGCT 1326
 D F K N D Y T C R L W S D S R H S R Q V L L L O D S F M (N) C S D S I 286
 ATCAATGCTTCTTCTGCTGCTGCTGCTTATTCATGAGGCTCAGGTCCGGGAAAGACTGATGGTCCACTGTGACAGCAAGACAGTAAATGCAAAATCGGAT 1428
 I (N) G S P R A L G P I H E A Q V G E R L M V H C D S K T G N A N T D 320
 TTCATCTGGGTGGTCCAGATAACAGACTGCTAGAGCGGATAAAGAGATGGAAGAACTTTTACGTTTTCACAAATGGAAGTCTGGTTATAGAAAGCCCTCGT 1530
 P I H V G P D N R L L E P D K E M E N F Y V P H (N) G S L V I E S P R 354
 TTTGAGATGCTGGAGTGTATTTCTGTATCGCAATGAAT AAGCAAGCCCTGTAAATGAACTGTGACGCTACAAATAAATGAGCAATTTCACTGTAAGC 1632
 F E D A G V Y S C I A M N K O R L L (N) E T V D V T I (N) V S (N) F T V S 388
 AGATCCATGCTCATGAGCATTAAACAGCTTTTACCACTCTCTGCTGCTTGGTGGCAGTATCGTTTGGTACTTTTGTACCTCTATCTGCTGCTGCTGCT 1734
 R S H A H E A P N T A P T T L A A C V A S I V L V L L Y L Y L T P C 422
 CCCTCGAAGTGTAAACCAAGAGACAGAAAAATATGCTACACCAAGCAATGCCCTTCTATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1836
 P C K C K (T) K R O K N M L H O S N A H S S I L (S) P G P A (S) D A (S) A D 456
 GAACGGAAGGAGGTCAGGTAAGAGAGTGGTGTGTTTGGAAACCCCTGAAGGACTGTCAGCAGGGGAGAACGGGAAAGTCAAGCTCTTTCCAGGAGGCA 1938
 E R K A G A G K R V V F L E P L K D T A A G O N G K V R L P P S E A 490
 GTGATAGCTGAGGGCATCCTAAAGTCCACGAGGGGAAATCTGACTCAGATTGAGTCAATTCAGTGTGTTTCTGACACACTTTTGTGGGCTGCTCACTTAATT 2040
 V I A E G I L K S T R G K (S) D (S) D (S) V P S D (T) P P V A (S) T • 522
 GTGCTATATTTGATGTCATAATTTAATCTGTTCA TATTTAACTTTGTTGGTCTGCAAAATAAAGCAGCAGGACAGAAATGTTGTTGTTGTTGTT 2142
 TTGAAATACAAACAAATTTCTCTTAAATGATTTGTTAGGAAATGAGGTAAGTACTTCACTTCTCAATGTCGACAGAAAGATGCGGTTGTTTCCAAAGTT 2244
 TANGTCTAGATCACAATATCTTAGCTTTTAGCACTATTGTTAATTTAGAGTAGGCCCAAAAGTGATATGACTCCCATTTGCTTTATTTAGGATATGA 2346
 AAGAAAAATAAATTTATGATATGATGCTCTTAAAAATAGACTTGTCTAACTTACTAGTACAGAGTTATTTTAAAGAAAAACACTAGTGTCCAAATTTCA 2448
 TTTTAAAAAGATGTAGAAAGAAAGAAATCAAGCA TCAATTAATTTAAGCCCTAAAGCAAGTTAGATTGCGGTTATTTCAGC CAAATTTACCGTTTATGACC 2550
 AGAATGAATAGACTACATGATAAATGTTACTGGATAATGCCACATCTATATGGTGTATAGAAATAGTGAAGGAAAGTACATTTGTTGCTGCTGTTT 2652
 CATTTGTGATCTCTCCCATTTCTGATTCTTGTACAAAGATCTCATGAAAAATTTAAAGT CATCAATTTGTTGCCATAAATATGTAAGTGTCAATACC 2754
 AAAATGTCTCAGTAATCTCTTAAATCCCTGTTCTAGCAAACTAAATATGTTTCAATGCTGCTGTTATATGTAATCTTAAATATGTTGAATATTAATAA 2856
 CCCTACTGTACTGTGCTTGGACATTGAAATTAATGTAATATATGTAATCTGTGACTGATATTTGTITTAATTTGGCTATTTAAAAACATAAATCTAATA 2958
 TGTCTTATGTTATCAGATTATGCTAATTTGTAAGGACCACTGATAGCAATCTCTCTCCAAATTTCTTATAGTAAAGTTGATTTTTTTAAAGGGGGAG 3060
 GGAAGGCTTTAAATGTTCTAGATCAATTTATACCTTCCGTATGAGCTTTTACTCTGATATCATTTGCACTTTAGCCAGATCCAGAAAAACATCAATTTA 3162
 TTTTGAACAAGTGAGAGCCAGGAGACTCTTATATCTGCTCTGCTTTGAGGCAATCAAGTACCTCTCTGAACCTAGGTTCCCTCATCTGTAAAC 3264
 AAAGGTTTCAGACAGATGGTGTTAAAGTTTCTCCCATACCTGCAATGAATGATTTCTTGGTGTATAGGATCATCACAGACCTATACCTGCTTCTGAA 3366
 ACTCTACCATCACTGAAAGAAATACAGGAATGGGATTAAGATGACTAGCATGAGAGTGTACAGCTTGAAGAGATGTTCCACATCATCTCCAGCTCTCTCT 3468
 CTTTTCTCAGGACAAA TGAAGCCGAGAGAAATACGACCTGTGTAAAGTCAAACTGCGGAGGAAAGAGGAGAGCTGGGTTTAGCATTCTCCCTGGTG 3570
 AAGATTGGAAGTCCAAAGAAATGACTCTCTTTTAAAGGATGGGCAATAAAGTGTATCAAAAATTGCAAGGAGAAATCAAGATGATGCTCCTGGGCTA 3672
 AGAAGAAGATAATTTTAAAGAAATGCGAGTGGCAAGTGAATAATTCAGATAGTAGATAAGATAGAAATCAACCTGACTGCTAGTA 3769

B)




Figure 2:




Figure 3:

A) Cancer Profiling Array I






Figure 3:**B) Cancer Profiling Array II**

Figure 3:**C)****D)**

Lung	A549	Prostate	DU145
	NCI-H460		PC3
	NCI-H1299		
Colon	HCT-116	Skin	SK-MEL-28
	HCT-116 p21-/-		SK-MEL-5
	HCT-116 p53-/-		SK-NSH
	HCT-15	Brain	IMR-32
	HT-29		U-87MG
Breast	MDA-MB4355	Kidney	786-O
	MDA-Mb231	Liver	ACHN
	MCF7	Colon	HepG2
Ovary	SKOV3	Osteosarcoma	Colo589
	HeLa		U2-OS
Cervical		Epidermis	A431




Figure 4:

Figure 4:**C)**

SEQ ID NO: 1**hS30-21616/DEGA cDNA sequence:**

The open reading frame is shown in upper case. Bold letters = start and stop codons. For more info on sequence, see Figure 1 of manuscript.

ggggctcctgcagcctcccgagtgcgagagaggcggggccgcccgcctgccgcccggctgcc
tgcgccccctcccgcgcccccggtctgggagcggggcgccccgcgcgcgggcacacgg
cggccagagcgccgaggcggtaccttcagcctgcaatgagaggaaccgggagagcccc
cgggagccagcgaagagcttggctgctgcgtccagggctgctgctgccgcccgggtgc
ttga
aactcctcaaagttgagagccggctagaggggtgccgccccgcccgggagccggaggggaaag
gaagtcgggaggtgcaagagtgcagacacggacagacggacgcgcagaccttcggaag
gcactgcgtaggcagcctccccggagcccacgaggctccccagcaccgttcactgggtgg
gaggctgagccgggtgaaaagacaccgggaagagactcagaggcgaccata**ATGTCGTT**
ACGT
GTACACACTCTGCCACCCTGCTTGGAGCCGTCGTCAGACCGGGCTGCAGGGAGCTGCT
GTGTTTGCTGATGATCACAGTGAAGTGTGGGCCCTGGTGCTCTGCGGTGTGCCCCACCG
CTTGCACTCTGTGCCACTGACATCGTCAGCTGCACCAACAAAAACCTGTCCAAGGTGCCT
GGGAACCTTTTCAGACTGATTAAGAGACTGGACCTGAGTTATAACAGAATTGGGCTTCT
GGAT
TCTGAGTGGATTCCAGTATCGTTTGCAAAGCTGAACACCCTAATTCTTCGTCATAACAA
CATCACCAGCATTTCCACGGGCAGTTTTTCCACAACCTCCAAATTTGAAGTGTCTTGACT
TATCGTCCAATAAGCTGAAGACGGTGAAAAATGCTGTATTCCAAGAGTTGAAGTTCTG
GAAGTGCTTCTGCTTTACAACAATCATATATCTATCTCGATCCTTCAGCGTTTGGAGG
GCTC
TCCCAGTTGCAGAACTCTACTTAAGTGGAATTTTCTCACACAGTTTCCGATGGATTT
GTATGTTGGAAGGTTCAAGCTGGCAGAACTGATGTTTTTAGATGTTTCTTATAACCGAA
TTCCTTCCATGCCAATGCACCACATAAATTTAGTGCCAGGAAAACAGCTGAGAGGCATC
TACCTTCATGGAAACCCATTTGTCTGTGACTGTTCCCTGTACTCCTTGCTGGTCTTTTG
GTAT
CGTAGGCACTTTAGCTCAGTGATGGATTTTAAGAACGATTACACCTGTGCGCTGTGGTC
TGACTCCAGGCACTCGCGTCAGGTAAGTCTGCTCCAGGATAGCTTTATGAATTGCTCTG
ACAGCATCATCAATGGTTCCTTTCGTGCGCTTGGCTTTATTCATGAGGCTCAGGTCGGG
GAAAGACTGATGGTCCACTGTGACAGCAAGACAGGTAATGCAAATACGGATTTTCATCTG
GGTG
GGTCCAGATAACAGACTGCTAGAGCCGGATAAAGAGATGGAAAACCTTTTACGTGTTTCA
CAATGGAAGTCTGGTTATAGAAAGCCCTCGTTTTGAGGATGCTGGAGTGTATTCTTGTA
TCGCAATGAATAAGCAACGCCTGTTAAATGAACTGTGGACGTCACAATAAATGTGAGC
AATTTCACTGTAAGCAGATCCCATGCTCATGAGGCATTTAACACAGCTTTTACCACTCT
TGCT
GCTTGCGTGGCCAGTATCGTTTTGGTACTTTTGTACCTCTATCTGACTCCATGCCCCCTG
CAAGTGTAACCAAGAGACAGAAAAATATGCTACACCAAGCAATGCCCATTCATCGA
TTCTCAGTCCTGGCCCCGCTAGTGATGCCTCCGCTGATGAACGGAAGGCAGGTGCAGGT
AAAAGAGTGGTGTTTTTTGAACCCCTGAAGGATACTGCAGCAGGGCAGAACGGGAAAGT
CAGG

CTCTTTCCAGCGAGGCAGTGATAGCTGAGGGCATCCTAAAGTCCACGAGGGGGAAATC
TGA CTCAGATTCAGTCAATTCAGTGTCTTCTGACACACCTTTTGTGGCGTCCACTTAAT
ttgtgcctatatatttgatgatgtcataatttaactgttcatatttaactttgtgtgtg
gtctgcaaaaataaacagcaggacagaaattgtgttgttttgttctttgaaatacaacca
aatt
ctcttaaaatgattggttaggaaatgaggtaaagtacttcagttcctcaatgtgccagag
aaagatggggttgttttccaaagtttaagttctagatcacatatcttagcttttagca
ctattggtaatttcagagtagggcccaaaggtgatatgactcccattgtccctttattta
ggatattgaaagaaaaataaactttatgtattagtgtcctttaaaaatagacttttgc
aact
tactagtaccagagttatttttaagaaaaacactagtgtccaatttcatttttaaaaga
tgtagaagaagaatcaagcatcaattaattataaagcctaagcaagtttagattttgg
gggttattcagccaaaattaccgttttagaccagaatgaatagactacactgataaaat
gtactggataatgccacatcctatatggtgttatagaaatagtgcaggaaagtacatt
tgtt
tgccgtgtcttttcattttgtacattcttcccattctgtattcttgtacaaaagatctda
ttgaaaatttaaggtcatcataatttgttggcataaataatgtaagtgtcaataccaaaa
tgtctgagtaacttcttaaatccctgttctagcaaaactaatattgggtcatgtgttgt
gtatatgtaaatcttaaatatgtgaactattaaatagaccctactgtactgtgtcttg
gaca
tttgaattaatgtaaatatatgtaatctgtgacttgatattttgtttttattttggctatt
taaaaaacataaatctaaaatgtcttatgttatcagattatgctattttgtataaagcac
cactgatagcaaatctctctccaaaattcttatagtaaagttgatttttttaagggggg
aggggaaggctttaatgtgttctagatcaatttataccttccgtatgacgttttactct
gata
tcattgtgcactttagccagatccagaaaacactcaaattttattttgcaacaagtgaga
gccaggagacctccttattatcctgtctctgctttgaggcaatcaagtacctctctg
aacctagggttcctcatctgtaaaacaaaggttcagaccagatgggtgtttaagggttc
tccccatactggaatgaatgatttcttgggtggtattagcatcatcacagacctatactt
gctt
tctgaaactctaccacatactgaaggaatacaggaatgggattaagatgactagcatag
cagtgtacagcttgaagagatgttccacatcatcactccagctccttctcttttctcag
ggacaaatgaggccagagagaatacgacctgtgtaaggtcaaacagtgaggcagggaag
aaggagagctggggttttagcattctccctggtgaagattgggaggtccaaagaaatgact
cctt
tttaagggtatgggcataaaaaagtgatcaaaacattgcaaaggagaatcaaagattgat
tgtcctggggctaagaaagaagataatttttaagaatgggagtgaggcaacagtgaaaa
atattgcagataagtagataaggatagaagatcaaccactgactggtagta

SEQ ID NO:2**hS30-21616/DEGA amino acid sequence:**

MSLRVHTLPTLLGAVVRPGCRELLCLLMITVTVGPGASGVCPTACICATDIVSCTNKNL
SKVPGNLFRLIKRLDLSYNRIGLLDSEWIPVSFAKLNTLILRHNNITSISTGSFSTTPN
LKCELDLSSNKLKTVKNAVFQELKVLEVL LLYNNHISYLDPSAFGGLSQLQKLYLSGNFL
TQFPMDLYVGRFKLAELMFLDVSYNRIPSPMPHHINLVPGKQLRGIYLHGPNFVCD CSL
YSL L

VFWYRRHFSSVMDFKNDYTCRLWSDSRHSRQVLL LQDSFMNCSDSIINGSFRALGFIHE
AQVGERLMVHCDSKTGNANTDFIWVGPDNRLLLEPDKEMENFYVFHNGSLVIESPRFEDA
GVYSCIAMNKQRLNETVDVTINVSNFTVSRSHAHEAFNTAFTTLAACVASIVLVLLYL
YLTPCPCKCKTKRQKNMLHQSNHSSILSPGPASDASADERKAGAGKRVVFLEPLKDTA
AGQN

GKVRLEFPSEAVIAEGILKSTRGKSDSDSVNSVFS DTPFVAST . . .

SEQ ID NO: 3

Polynucleotide sequence of mouse S30-21616, *mS30-21616/DEGA*.

ATGGTGAGCCCCAGCGCCTCAGGAATGTGCCCCACTGCTTGCATCTGTGCC
ACCGACATTGTCAGCTGCACCAACAAAAACCTATCTAAGGTGCCCGGGAA
CCTTTTCAGACTGATTAAAAGACTGGATCTGAGCTATAACAGAATCGGAC
TGTTGGATGCCGACTGGATCCCGGTGTCGTTTGTCAAGCTGAGCACCTTAA
TTCTTCGCCACAACAACATCACCAGCATCTCCACGGGCAGTTTCTCCACAA
CCCCAAATTTAAAGTGTCTGGACTTATCATCCAATAGGCTGAAGTCGGTA
AAGAGTGCCACATTCCAAGAGCTGAAGGCTCTGGAAGTACTGCTGCTGTA
CAACAACCACATTTCCCTATCTGGACCCCGCAGCGTTCGGGGGGGCTTTCCCA
CTTGCAAGAACTCTATCTGAGTGGGAACTTTCTCACACAGTTCCCTATGGA
TTTGTATACTGGGAGGTTCAAGCTGGCTGATCTGACATTTTATAGATGTTTC
CTATAATCGAATCCCTTCCATACCGATGCACCATATAAACTTAGTGCCGGG
GAGACAGCTGAGAGGCATCTACCTTCACGGGAACCCATTTGTATGTGACT
GTTCTCTGTACTCGTTGCTGATCTTTTGGTACCGTAGGCACTTTAGCTCCGT
GATGGATTTTAAGAATGACTATACCTGTCGCCTGTGGTCTGACTCCAGGCA
CTCCCACCAGCTGCAGCTGCTCCAGGAGAGCTTTCTGAACTGTTCTTACAG
CGTTATCAACGGCTCCTTCCACGCACTTGGCTTTATCCACGAGGCTCAGGT
TGGGGAGAGGGCGATCGTCCACTGTGACAGCAAGACTGGCAATGGAAAT
ACTGATTTTCATCTGGGTCGGTCCCGATAACAGGCTGCTGGAGCCAGATAA
AGACATGGGGAACTTTCGTGTGTTTTACAACGGAAGTCTGGTCATAGAGA
ACCCTGGCTTTGAGGACGCCGGGGTATATTCTTGTATCGCAATGAACAGG
CAGCGGCTGTAAACGAGACGGTGGATATCATGATCAACGTGAGCAATTT
CACCATAAACAGATCCCACGCCACGAGGCGTTTAACACGGCCTTTACCA
CCCTGGCTGCCTGCGTGGCCAGTATAGTT
CTAGTGCTACTGTATCTGTACCTGACGCCGTGCCCATGCAAATGCAAAGCC
AAGAGACAGAAAAACACGCTGAGCCAAAGCAGTGCCCACTCGTCCATTCT
CAGTCCTGGCCCCACTGGCGATGCCTCTGCTGACGATCGGAAGGCAGGTA
AAAGAGTCGTGTTTCTGGAGCCCCCTGAAGGACACGGCGGCCGACAGAAT
GGCAAAGTCAAGCTTTTCCCCAGTGAGACCGTTATAGCCGAGGGCATCTT
AAAGTCCACCAGGGCAAAGTCTGACTCAGACTCAGTCAATTCCGTGTTCT
CAGACACACCCTTTGTGGCATCCACTAG

SEQ ID NO: 4

Amino acid sequence of mouse S30-21616 polypeptide, mS30-21616/DEGA.

MVSPSASGMCPTACICATDIVSCTNKNLSKVPGNLFRLIKRLDLSYNRIGLLDA
DWIPVSFVKLSTLILRHNNITSISTGSFSTTPNLKCLDLSSNRLKSVKSATFQEL
KALEVLLLYNNHISYLDPAAFGGLSHLQKLYLSGNFLTQFPMDLYTGRFKLA
DLTFLDVSYNRIPSIPMHINLVPGRQLRGIYLHGNPFVCDCLYSLIFWYRR
HFSSVMDFKNDYTCRLWSDSRHSHQLQLQESFLNCSYSVINGSFHALGFIHE
AQVGERAIVHCDSKTGNGNTDFIWVGPDNRLLPEPKDMGNFRVFYNGSLVIE
NPGFEDAGVYSCIAMNRQRLNETVDIMINVSNFTINRSHAHEAFNTAFTTLA
ACVASIVLVLLYLYLTPCPCKCKAKRQKNTLSQSSAHSSILSPGPTGDASADD
RKAGKRVVFLEPLKDTAAGQNGKVKLFPSETVIAEGILKSTRAKSDSDSVNSV
FSDTPFVAST

SEQ ID NO: 5

**Amino acid sequence of human S30-21616/DEGA polypeptide
lacking transmembrane (TM) domain, -TM hS30-21616/DEGA.**

MSLRVHTLPTLLGAVVRPGCRELLCLLMITVTVGPGASGVCPTACICATDIVS
CTNKNLSKVPGNLFRLIKRLDLSYNRIGLLDSEWIPVSFAKLNTLLRHNNITSI
STGSFSTTPNLKCLDLSSNKLKTVKNAVFQELKVLEVLLLYNNHISYLDPSAF
GGLSQLQKLYLSGNFLTQFPMDLYVGRFKLAELMFLDVSYNRIPSPMPHHIN
LVPGKQLRGIYLHGNPFVCDCLYSLLVFWYRRHFSSVMDFKNDYTCRLWS
DSRHSRQVLLLQDSFMNCSDSIINGSFRALGFIHEAQVGERLMVHCDSKTGNA
NTDFIWVGPDNRLLLEPDKEMENFYVFHNGSLVIESPRFEDAGVYSCIAMNKQ
RLNETVDVTINVSNFTVSRSHAHEAFNT

SEQ ID NO:6 Leucine Zipper Motif
LYLSGNFLTQFPMDLYVGRFKL

SEQ ID NO: 7 Leucine Rich Repeat 1
VCPTACICATDIVSCTNKNLSKVPGNLFRLIKR

SEQ ID NO: 8 Leucine Rich Repeat 2
SFAKLNTLILRHNNI

SEQ ID NO: 9 Leucine Rich Repeat 3
TSISTGSFSTTPNLKCLDLSSNKLKTVKNAVFQELKVLEVLLLYN

SEQ ID NO: 10 Leucine Rich Repeat 4
LKVLEVLLLYNNHISYLDPSAFGG

SEQ ID NO: 11 Leucine Rich Repeat 5
LSQLQKLYLSGNFLTQFPMDLYVG

SEQ ID NO: 12 Leucine Rich Repeat 6
LAELMFLDVSYNRIPSMPPMHINLV

SEQ ID NO: 13 Immunoglobulin (Ig)- domain
FRALGFIHEAQVGERLMVHCDSKTGNANTDFIWVGPDNRLLLEPKEMENFY
VFHNGSLVIESPRFEDAGVYSCIAMNKQRLLNETVDVTIN

SEQ ID NO: 14 PCR Primer 1
5'-ATG TCG TTA CGT GTA CAC ACT CTG - 3'

SEQ ID NO: 15 PCR Primer 2
5'-TTA AGT GGA CGC CAC AAA AGG TGT- 3'

SEQ ID NO:16 S30-21616/DEGA Gene -specific Reverse Primer
5'-AAC TCA GGT CCA GTC TCT TAA TCA G- 3'

SEQ ID NO:17 Forward primer
5'- ATG TCG TTA CGT GTA CAC ACT CTG-3'

SEQ ID NO:18 Reverse Primer

5'- CAA AAT GAA AAG ACA GGC AAA CAA ATG-3'

SEQ ID NO:19 Forward Primer for S30-21616/DEGA-EGFP Fusion Construct

5' ATC CTC GAG GCG ACC ATA ATG TCG TTA CGT GTA CAC ACT 3'

SEQ ID NO:20 Reverse Primer for S30-21616/DEGA-EGFP Fusion Construct

5' GAT CAC CGG TGC AGT GGA CGC CAC AAA AGG TGT GTC 3'

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.